Multi-Cancer Detection (MCD) Research

A rack test tubes with blood samples.New technologies under development can detect multiple components of a growing cancer, such as circulating tumor cells, tumor DNA, and other analytes, in blood or other body fluids. These tests look for circulating tumor cells, tumor DNA, and other substances that might be present in several different types of cancer. Some of these tests under development are trying to detect cancers at early stages.  These kinds of tests are collectively known as either Multi-Cancer Detection assays (MCDs) or sometimes Multi-Cancer Early Detection assays (MCEDs), or M.C.E.D.s (MCEDs). NCI uses Multi-Cancer Detection (MCD) assays.

The idea of testing for multiple types of cancers simultaneously with a single MCD test is a new and exciting concept for cancer screening. However, there are many unanswered questions about using this very different kind of test, including:

  • what additional testing is necessary and after a positive test to confirm the presence of a cancer;
  • what types of cancers are detected by an MCD test and at what stages are these cancers;
  • which people will derive a net benefit from MCD screening; and
  • whether MCD tests can be successfully implemented in real-world practice.

This webpage is a gateway to DCP efforts surrounding study of MCD assays for cancer screening.

Update on National Cancer Institute (NCI) Vanguard Study on Multi-Cancer Detection

As a central component of the Cancer Moonshot, the National Cancer Institute is soon to launch a new research network to study cancer screening, including evaluating the effectiveness new blood tests for the detection of one or more cancers to prevent cancer-related deaths. If found to be useful, these type of tests provide the opportunity for less invasive tools for the early detection of cancer. NCI will begin enrolling 24,000 healthy people age 45- 70 in 2024 to lay the groundwork for the later, larger study that will enroll up to 225,000 people. The vanguard study is being funded in part by 21st Century Cures Act Cancer Moonshot funds.

Pre-Application Webinars

The NCI Division of Cancer Prevention released three funding opportunities for the Cancer Screening Research Network (CSRN) and will hold pre-application interactive webinars. The first webinar will provide an overview of the Network, and address all three grants. There will be three subsequent RFA-specific webinars. NCI staff will discuss the funding opportunities and answer questions from prospective applicants. Participants are asked to submit their questions ahead of time to CSRN@nih.gov by the Wednesday preceding the webinar of interest by 11:59 PM EST. Participation in the webinars is optional.

All CSRN Grants

(RFA-CA-23-020, RFA-CA-23-021, RFA-CA-23-022)
Date: Friday, December 9, 2022
Time: 1:00 pm ET
Register now

RFA Specific Sessions

RFA-CA-23-021: NCI Cancer Screening Research Network: Statistics and Data Management Center
Date: Friday, December 16, 2022
Time: 11:00 am ET
Register now

RFA-CA-23-022: NCI Cancer Screening Research Network: Coordinating and Communication Center (UG1 Clinical Trial Required)
Date: Friday, December 16, 2022
Time: 12:00 pm ET
Register now

RFA-CA-23-020: NCI Cancer Screening Research Network: ACCrual, Enrollment, and Screening Sites (ACCESS) Hub
Date: Friday, December 16, 2022
Time: 1:00 pm ET
Register now

MCD Research Teams

The National Cancer Institute is actively working with researchers across the Institute and at other federal agencies to investigate all aspects of multi-cancer detection tests. Learn more about how these teams are addressing different, but related aspects of the science:

Questions and Answers

Cancer Screening with Multi-Cancer Detection (MCD) Tests

  • What are Cancer Screening Tests?
  • What Kind of Tests are Used to Screen for Cancer?
  • Does a Positive Cancer Screening Test Mean I Have Cancer?
  • What are Multi-Cancer Detection (MCD) Tests?
  • And more...

View all Questions and Answers

NCI Board of Scientific Advisors Presentation
June 15, 2022

On Wednesday, June 15, 2022, the Division of Cancer Prevention is presenting a request to fund an RFA entitled “Cancer Screening Network to Evaluate Multi-Cancer Detection Assays for Clinical Utility in Cancer Screening.”

Date: Wednesday, June 15, 2022
Time: 2:45 p.m. ET

Meeting agenda (PDF, 211 KB)
View the slides (PDF, 2 MB)

Recording of presentation available at https://videocast.nih.gov/watch=45621&start=6796

Liquid Biopsy Consortium

Liquid Biopsy: Blood, Urine, Sputum.NCI sponsors this Academic/Industrial Partnership program designed to advance and validate Liquid Biopsy technologies specifically targeted for early stage cancer detection. Liquid biopsy uses body fluids such as blood, urine, saliva, stool, and sputum from patients suspected to have early stage cancer as well as those at high risk of developing cancer. The Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment Consortium is also working on methods to distinguish cancer from benign disease; or aggressive from indolent cancers.